Sandoz To High Court: Error To Require Approval Before 180-Day Notice
WASHINGTON, D.C. — In a Feb. 10 opening brief in its high-stakes suit with Amgen Inc., Sandoz Inc. argues that the Federal Circuit U.S. Court of Appeals erred by forcing biosimilar...To view the full article, register now.
Already a subscriber? Click here to view full article